Novel PiuC, PirA, and PiuA mutations leading to in vivo cefiderocol resistance progression in IMP-16- and KPC-2-producing Pseudomonas aeruginosa from a leukemic patient

Pseudomonas aeruginosa is an opportunistic pathogen capable of causing severe infections in immunocompromised individuals, who often require prolonged antibiotic therapy. The emergence of carbapenemase-producing P. aeruginosa has further complicated the management of nosocomial infections, limiting...

Descripción completa

Detalles Bibliográficos
Autores: Viñes, Joaquim|||0000-0003-0709-5236, Herrera, Sabina|||0000-0002-5057-354X, Vergara, Andrea|||0000-0002-5046-4490, Roca, Ignasi|||0000-0002-1800-1576, Vila Estapé, Jordi|||0000-0002-8025-3926, Aiello, Tommaso Francesco|||0000-0003-4441-6318, Martínez, José Antonio, del Río, Ana, Lopera, Carlos, Garcia-Vidal, Carolina|||0000-0002-8915-0683, Casals-Pascual, Climent|||0000-0002-0867-8954, Soriano Viladomiu, Alex|||0000-0002-9374-0811, Pitart, Cristina|||0000-0002-3083-7915
Tipo de recurso: artículo
Fecha de publicación:2025
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:321003
Acceso en línea:https://ddd.uab.cat/record/321003
https://dx.doi.org/urn:doi:10.1128/spectrum.01928-24
Access Level:acceso abierto
Palabra clave:Pseudomonas aeruginosa
Carbapenem-resistant
Cefiderocol
PiuA
PiuC
PirA
Leukemia
Oxford Nanopore
Descripción
Sumario:Pseudomonas aeruginosa is an opportunistic pathogen capable of causing severe infections in immunocompromised individuals, who often require prolonged antibiotic therapy. The emergence of carbapenemase-producing P. aeruginosa has further complicated the management of nosocomial infections, limiting therapeutic options. Cefiderocol has recently emerged as a promising antipseudomonal agent, using the bacterial iron transport system to gain entry into the cell; however, there have been reports of P. aeruginosa resistant to cefiderocol. We describe the in vivo cefiderocol resistance progression of four consecutive P. aeruginosa isolates from one patient with T-cell acute lymphoblastic leukemia. Analysis of potential genes involved in cefiderocol transport resulted in three genes mutated in two resistant isolates. One isolate presented a S116F substitution in PiuC, and the other presented a deletion of 29 amino acids in the signal peptide of PiuA and a STOP substitution in PirA, resulting in the deletion of a piece of the channel. These mutations increased 24- and 64-folds the cefiderocol minimum inhibitory concentration, respectively. The mutations in the aforementioned genes may directly impact siderophore internalization, thereby contributing to an elevation in the MIC of the antibiotic. IMPORTANCECarbapenem-resistant Pseudomonas aeruginosa poses a significant challenge due to its broad antibiotic resistance. Cefiderocol is a novel antibiotic aimed at combating infections caused by such organisms. However, if these pathogens develop resistance to this new drug, it hinders treatment efficacy and options. Therefore, it is crucial to identify and describe mutations in the genes involved in the uptake of cefiderocol to find better treatment strategies for patients infected with multidrug-resistant P. aeruginosa.